Enodia and Pfizer sign agreement to develop Sec61-targeting drugs
Enodia Therapeutics and Pfizer entered a research and licensing agreement on October 13 to develop small-molecule Sec61 inhibitors. Enodia will perform the discovery-stage work across multiple targets, while Pfizer will assume responsibility for clinical development, production, regulatory matters and commercialization after the collaboration period. The arrangement could provide Enodia with more than $500 million through upfront, milestone and royalty payments.
Why it matters
The agreement gives Enodia access to Pfizer's downstream development and commercial capabilities while creating potential future payments for the private biotech. Enodia said the upfront and milestone payments would provide capital for its own pipeline without requiring equity financing.
Key facts
- 1The potential deal value is more than $500 million, including upfront, research, development and sales milestones, and tiered royalties on net sales. sttinfo.fi
- 2Enodia is responsible for screening, refining and advancing Sec61 inhibitor candidates for multiple targets during the discovery phase. bioxconomy.com
- 3Pfizer is set to oversee clinical, manufacturing, regulatory and commercial work once the collaboration term concludes. sttinfo.fi
- 4The upfront payment amount and the covered therapeutic areas have not been disclosed. bioxconomy.com
Open questions
- The amount of Pfizer's upfront payment is undisclosed.
- The therapeutic areas covered by the collaboration have not been disclosed.
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.